低分子量铁螯合物或可替代钆基对比剂用于T1加权增强MRI
本研究合成Fe-DTPA与Fe-tCDTA两种低分子量铁螯合物,在1.5T、3T、7T血清体模及五只小鼠每组的人乳腺癌MDA-231移植瘤模型中,与钆喷酸葡胺比较T1对比效果;结果显示铁螯合物在适度提高浓度后可产生相似对比效果,DCE定量参数与钆剂相关性好。
要点
- Fe-tCDTA与Fe-DTPA的r1弛豫率分别约为钆喷酸葡胺的1/2和1/5,但适度提高浓度可获相似T1对比效果。
- DCE-MRI容积转运常数在铁螯合物与钆喷酸葡胺之间相关性好(Fe-tCDTA R=0.99,Fe-DTPA R=0.97),提示铁剂可用于DCE定量。
- 铁基对比剂可能成为T1加权增强MRI的替代选择,并可能有助于提升MRI安全性。
核心结论
- 铁基对比剂作为T1加权MRI增强的替代方案具有前景,并可能有助于提升MRI安全性。
研究设计与样本
- 动物实验经当地伦理委员会批准;每组五只小鼠植入人乳腺癌MDA-231细胞系;在1.5T、3T、7T下用血清体模比较两种铁螯合物与钆喷酸葡胺的T1对比效果;体内于第1天静脉注射Fe-DTPA或Fe-tCDTA行DCE-MRI,第2天对同一肿瘤行钆喷酸葡胺DCE-MRI,定量DCE图用软件生成并以单尾Pearson相关检验比较。
诊断标准与关键数值
- 在血清中(0.94T,室温)Fe-tCDTA的r1=2.2 mmol-1·sec-1、r2=2.5 mmol-1·sec-1,Fe-DTPA的r1=0.9 mmol-1·sec-1、r2=0.9 mmol-1·sec-1,分别约为钆喷酸葡胺(r1=4.1 mmol-1·sec-1、r2=4.8 mmol-1·sec-1)的1/2和1/5;适度提高浓度后,铁螯合物在体外血清、体内血液及乳腺癌移植瘤DCE-MRI中产生的T1加权对比效果与钆喷酸葡胺相似;同一肿瘤中Fe-tCDTA的容积转运常数与钆喷酸葡胺相关性Pearson R=0.99(P=.0003),Fe-DTPA Pearson R=0.97(P=.003)。
临床应用与阅片要点
- 作者认为铁基对比剂作为T1加权MRI增强的替代方案具有前景,并可能有助于提升MRI安全性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Purpose To synthesize two low-molecular-weight iron chelates and compare their T1 contrast effects with those of a commercial gadolinium-based contrast agent for their applicability in dynamic contrast material-enhanced (DCE) magnetic resonance (MR) imaging. Materials and Methods The animal experiments were approved by the local ethics committee. Two previously described iron (Fe) chelates of pentetic acid (Fe-DTPA) and of trans-cyclohexane diamine tetraacetic acid (Fe-tCDTA) were synthesized with stability constants several orders of magnitude higher than those of gadolinium-based contrast agents. The T1 contrast effects of the two chelates were compared with those of gadopentetate dimeglumine in blood serum phantoms at 1.5 T, 3 T, and 7 T. For in vivo studies, a human breast cancer cell line (MDA-231) was implanted in five mice per group. The dynamic contrast effects of the chelates were compared by performing DCE MR imaging with intravenous application of Fe-DTPA or Fe-tCDTA on day 1 and DCE MR imaging in the same tumors with gadopentetate dimeglumine on day 2. Quantitative DCE maps were generated with software and were compared by means of a one-tailed Pearson correlation test. Results Relaxivities in serum (0.94 T at room temperature) of Fe-tCDTA (r1 = 2.2 mmol-1 · sec-1, r2 = 2.5 mmol-1 · sec-1) and Fe-DTPA (r1 = 0.9 mmol-1 · sec-1, r2 = 0.9 mmol-1 · sec-1) were approximately twofold and fivefold lower, respectively, compared with those of gadopentetate dimeglumine (r1 = 4.1 mmol-1 · sec-1, r2 = 4.8 mmol-1 · sec-1). Used at moderately higher concentrations, however, iron chelates generated similar contrast effects at T1-weighted MR imaging in vitro in serum, in vivo in blood, and for DCE MR imaging of breast cancer xenografts. The volume transfer constant values for Fe-DTPA and Fe-tCDTA in the same tumors correlated well with those observed for gadopentetate dimeglumine (Fe-tCDTA Pearson R, 0.99; P = .0003; Fe-DTPA Pearson R, 0.97; P = .003). Conclusion Iron-based contrast agents are promising as alternatives for contrast enhancement at T1-weighted MR imaging and have the potential to contribute to the safety of MR imaging. © RSNA, 2017 Online supplemental material is available for this article.
引用
- Boehm-Sturm P, Haeckel A, Hauptmann R, et al. Low-Molecular-Weight Iron Chelates May Be an Alternative to Gadolinium-based Contrast Agents for T1-weighted Contrast-enhanced MR Imaging. Radiology. 2017. PMID: 28880786. doi:10.1148/radiol.2017170116
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。